PD-1 Primarily Targets TCR Signal in the Inhibition of Functional T Cell Activation

Cancer-immunotherapy targeting programmed cell death 1 (PD-1) activates tumor-specific T cells and provides clinical benefits in various cancers. However, the molecular basis of PD-1 function is still enigmatic. Especially, it is unclear which signaling pathway PD-1 primarily targets. Besides, the c...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizuno, Reina, Sugiura, Daisuke, Shimizu, Kenji, Maruhashi, Takumi, Watada, Mizuki, Okazaki, Il-mi, Okazaki, Taku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6455061/
https://www.ncbi.nlm.nih.gov/pubmed/31001256
http://dx.doi.org/10.3389/fimmu.2019.00630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6455061/
https://www.ncbi.nlm.nih.gov/pubmed/31001256
http://dx.doi.org/10.3389/fimmu.2019.00630

Ejemplares similares